Trials / Withdrawn
WithdrawnNCT02052219
BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Anthera Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the effect of blisibimod plus standard of care versus placebo plus standard of care alone on the proportion of subjects achieving improvement in renal disease parameters.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Blisibimod | Blisibimod administered subcutaneously |
| DRUG | Placebo | Placebo administered subcutaneously |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2016-10-01
- Completion
- 2021-10-01
- First posted
- 2014-02-03
- Last updated
- 2015-07-30
Source: ClinicalTrials.gov record NCT02052219. Inclusion in this directory is not an endorsement.